Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug;41(8):633-640.
doi: 10.1007/s40266-024-01129-6. Epub 2024 Jul 9.

Pre-clinical Models for Geriatric Pharmacotherapy

Sarah N Hilmer  1 , Kristina Johnell  2 , John Mach  3
Affiliations
Review

Pre-clinical Models for Geriatric Pharmacotherapy

Sarah N Hilmer et al. Drugs Aging. 2024 Aug.

Abstract

With ageing of the population worldwide and discovery of new medications for prevention and management of age-related conditions, there is increasing use of medications by older adults. There are international efforts to increase the representativeness of participants in clinical trials to match the intended real-world users of the medications across a range of characteristics including age, multimorbidity, polypharmacy and frailty. Currently, much of the data on medication-related harm in older adults are from pharmacovigilance studies. New methods in pre-clinical models have allowed for measurement of exposures (such as chronic exposure, polypharmacy and deprescribing) and outcomes (such as health span functional measures and frailty) that are highly relevant to geriatric pharmacotherapy. Here we describe opportunities for design and implementation of pre-clinical models that can better predict drug effects in geriatric patients. This could improve the translation of new drugs from bench to bedside and improve outcomes of pharmacotherapy in older adults.

PubMed Disclaimer

Conflict of interest statement

S.H., J.M. and K.J. all conduct research on preclinical polypharmacy models.

Figures

Fig. 1
Fig. 1
Pre-clinical models for geriatric pharmacotherapy
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Wastesson JW, Canudas-Romo V, Lindahl-Jacobsen R, Johnell K. Remaining life expectancy with and without polypharmacy: a register-based study of Swedes aged 65 years and older. J Am Med Dir Assoc. 2016;17(1):31–5. 10.1016/j.jamda.2015.07.015 - DOI - PMC - PubMed
    1. Salvi F, Marchetti A, D’Angelo F, Boemi M, Lattanzio F, Cherubini A. Adverse drug events as a cause of hospitalization in older adults. Drug Saf. 2012;35(Suppl 1):29–45. 10.1007/BF03319101 - DOI - PubMed
    1. Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US emergency department visits for outpatient adverse drug events, 2013–2014. JAMA. 2016;316(20):2115–25. 10.1001/jama.2016.16201 - DOI - PMC - PubMed
    1. Wastesson JW, Fastbom J, Johnell K. Expanding the proportion of life with polypharmacy in Sweden: 2006–2013. J Am Med Dir Assoc. 2016;17(10):957–8. 10.1016/j.jamda.2016.07.006 - DOI - PubMed
    1. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365(21):2002–12. 10.1056/NEJMsa1103053 - DOI - PubMed

LinkOut - more resources